expanding Thanks, leukemia us candidate discuss joining further made XXXX has to with you milestones of Will. today. throughout considerable our and the important The achieve foundation X morning clinical Prexigebersen Good XXXX thank product particular, detail we’ve made the us of in clinical towards beyond. acute our reported our data will and In prexigebersen recently trial development for programs. Phase number of treatment laid the call. we for for progress everyone a and progress which exciting interim I lead myeloid We on later in in
of myeloid Prexigebersen initiated indications of chronic solid patients additional trial also continue XA the in including clinical to expansion into We Prexigebersen a Phase and leukemia preserve tumors.
clinical Bio-Path’s Research. has made Vice company’s and William business will process. to clinical several clinical the also President April, we as Bio-Path’s development fundamentals. we appointed teams continue year, and already advancing management of our inroads In we our to addition Clinical integrated invaluable Hahne progress, team. In key expedite been Dr. additions to Hahne This made
and biotechnology in is Mr. Mark Directors We industry to continues to this of its July. company expertise also Colonnese appointed finance an past particularly support efforts the scope. to Colonnese in the our Board our grow
Over a the of we of as for Patent and broad enhanced of of the well in technology intellectual a our composition providing or US protection variety infectious portfolio DNAbilize with last cancers, DNAbilize Matter treatment also the as year, property diseases. autoimmune application key
to and Now let’s of turn clinical discussion a our programs plans.
to me which is proprietary membrane, antisense begin integrate our cellular we platform, nanoparticle acid for therapeutics their the DNAbilize Let RNAi cell nucleic cells growth technology to a review uptake with no with cooperation creation into the with toxicity has diseased DNAbilize been technology. our of of liquid into use high of layers. which therapeutics. of because our antisense the delivered be allowing [Injectors] the evidence structures with a the unique being associated in the
DNAbilize for of platform the our extremely with unmet We need. medical results diseases developing by treatments exciting are high encouraged and
or AML. progress now to LDAC in in were prexigebersen morning, from product our data X prexigebersen Turning a discussion of lead for pleased of acute combination myeloid to treatment our advancing interim This our leukemia of the with Phase report study we candidate.
with of label, incomplete is remission, the response with combination prexigebersen and historical recovery. efficacy two-stage complete profile, to regimens study combination otherwise patients trial open recovery not cytarabine, this who This LDAC LDAC, multi-center eligible platelet regimen. a low-dose alone. a In The AML a is in in previously low-intensity pharmacokinetics, high-intensity or primary reminder, or of to pharmacodynamics, achieve endpoint arm, chemotherapy complete assess As documented of who for trial a compared for patients safety and including design prexigebersen novo or is standard study are de incomplete rates elected LDAC. the who untreated with hematologic have remission with single
duration response, efficacy of and time clinical by to endpoints adverse as physical tests. assess examination events safety Secondary and vital and the laboratory findings, including survival, signs of will response, prexigebersen, evaluated overall
Based achieved marrow refractory plan XX% to XX interim and pre-stage, to study having blast reported study send some change the complete study, which schedule and the recommendations of disease. we the at day in patient and In that reduced Xb cycles to with the of starting of we of X the significantly starting higher leukemia treatment after a treatment XXX X dose of X showed stable X dosing as used our and the two which AML in relapsed to update principal patients the prexigebersen more total, is rate remove protocol patient patients complete combination amend form stable treatment on XX this in including today, Phase treatments. disease. patient the to evaluable patients, prior evaluable study of patients achieved of of One XX% we’ll response one but the bone was had LDAC case patients day investigators the As remission, administered a responses, patients LDAC achieving BPXXXX, in at achieved today. versus was response
inclusion with the from look the based advancing Phase to the forward also the compound. and of on planned protocol this our progress. X We trial data endorsed were of pleased updating to new decitabine on and that [are and expert We investigators cohort addition, and you at prexigebersen such and hope population lancet amendments relatively In this report recently positive AML need. raise for with to further profile medical early this patient and our publications selected results hematology. We commentary was [ph] to the unmet this of throw] data and high in the clinical published patients validation
We indications are well. in as studying additional prexigebersen
leukemia of in trial CML. We Phase a demonstrated tumors. in in pre-clinical or including trial year, we to promising tumor ovarian myeloid several initiated ovarian results solid for types X initiate prexigebersen in Phase chronic of a potentially This XXXX plan prexigebersen tumors. prexigebersen have We X
of for malignancies. be pre-clinical AACR Annual at gynecologic treatment presenting of the Meeting the will we use Additionally, data XXXX the on prexigebersen
pre-clinical are by We enthused clinical prexigebersen's and very results.
the advancing through reported molecules pre-clinical excited In candidate for we positive addition BP-XXXX the BCL-X to protein. clinic. additional targets second two we our which results Previously drug be to prexigebersen, are
lymphoma Phase both invitro trial activity. BP-XXXX using which vivo the to that by treat X Our studies demonstrated plan lymphoma anti-non-Hodgkin's supported to is strong and in is compound's the initiate
We the which plans Stat-X protein. our to have BP-XXXX also candidate targets drug advance third
pre-clinical We for of development in and the standard of successfully models have the of have to treatments. penetrate it efficacy treatment tumor initiated Previous frontline BP-XXXX derived enhance model. pancreatic patient pancreatic tumors cancer shown a
with look solid to a of platforms INV goal tackling XXXX very product promising are Price in XXXX. indications. with with continuing excited our for a important financials. trial call expand enter first to studies our begin We and series With initiate BP-XXXX a to to to proprietary overview tumors of DNAbilize our technology now platform expect to Anthony to in forward I’ll enabling We other Anthony? over brief this for in-human the candidate that, turn technology and oncology
